Loading viewer...
investor_presentation
Format: PDF investor_presentation
© 2020 Tonix Pharmaceuticals Holding Corp.1 August 2020 Version P0244 8-17-20 (Doc 0695)Investor Presentation NASDAQ:TNXP
© 2020 Tonix Pharmaceuticals Holding Corp.1
Version P0244 8-17-20 (Doc 0695)Investor Presentation
© 2020 Tonix Pharmaceuticals Holding Corp.2Cautionary Note on Forward -Looking
Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture
operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform
Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”
“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on
Tonix’s current expectations andactual results could differ materially .There areanumber offactors that
could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These
factors include, butarenotlimited to,risks related tofailure toobtain U.S.Food andDrug Administration
clearances orapprovals andnoncompliance withitsregulations ;ourneed foradditional financing ;delays and
uncertainties caused bytheglobal COVID -19pandemic; substantial competition ;uncertainties ofpatent
protection andlitigation ;uncertainties ofgovernment orthird party payor reimbursement ;limited research
anddevelopment efforts anddependence upon third parties .Aswithanypharmaceutical under development,
there aresignificant risks inthedevelopment, regulatory approval andcommercialization ofnewproducts .
Theforward -looking statements inthispresentation aremade asofthedate ofthispresentation, even if
subsequently made available byTonix onitswebsite orotherwise .Tonix does notundertake anobligation to
update orrevise anyforward -looking statement, except asrequired bylaw.Investors should read therisk
factors setforth intheAnnual Report onForm 10-Kfortheyearended December 31,2019,asfiledwiththe
Securities andExchange Commission (the“SEC”) onMarch 24,2020, andperiodic reports andcurrent reports
filed with theSEConorafter thedate thereof .AllofTonix's forward -looking statements areexpressly
qualified byallsuch riskfactors andother cautionary statements .© 2020 Tonix Pharmaceuticals Holding Corp.3Tonix Pharmaceuticals
© 2020 Tonix Pharmaceuticals Holding Corp.Developing novel therapies for humanity
•A clinical- stage biopharmaceutical company committed to
discovering and developing innovative and proprietary new
therapeutics that address the needs of patients
•We focus on developing small molecules and biologics:
•CNS (pain, neurology, psychiatry, addiction)
•Immunology (vaccines, immunosuppression, oncology,
autoimmune disease)© 2020 Tonix Pharmaceuticals Holding Corp.4Our Pipeline –CNS Portfolio
Preview truncated — download the full document for the complete content.
investor_presentation
48 Pages
investor_presentation
45 Pages
Commerzbank